The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase.

By P. Kantor, A. Lucien, R. Kozak, G. Lopaschuk. Circulation Research, 2000

858 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Clinical Biochemistry, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/1f478226f3c23848c547c64ee2216e20fb2bf3b1